Live Analyst Rating Changes 35282 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Craig Wong-Pan
RBC

Craig Wong-Pan

RBC Capital
Wall Street Analyst
★★★☆☆
#1885
on 13Foresight · ranked by our own returns
59%
Success Rate
+2.9%
Average Return
36 of 61 calls profitable · +15.3% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 59% of Craig Wong-Pan's ratings turned a profit when each position was held for 1 year — averaging +2.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

31 Buy 61 Hold 5 Sell
Craig's Stock Coverage 18 ratings · 2026-09-28
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
AU:HLS
Healius Limited
 Sep 25, 2026 HOLD Sell
+126.1% avg upside
10 analysts
$0.42
10.57% Upside
 · ·
AU:TLX
Telix Pharmaceuticals
 Sep 21, 2026 BUY Strong Buy
+64.4% avg upside
14 analysts
$21.00
32.10% Upside
 -5.3% ·
AU:CSL
CSL
 Sep 15, 2026 BUY Strong Buy
+21.3% avg upside
16 analysts
$213.00
20.34% Upside
 +1.5% ·
AU:NAN
Nanosonics Limited
 Sep 15, 2026 BUY Buy
+60.7% avg upside
7 analysts
$3.75
27.07% Upside
 +2.1% ·
AU:RHC
Ramsay Health Care
 Sep 15, 2026 BUY Buy
-13.8% avg upside
14 analysts
$68.00
22.91% Upside
 +0.8% ·
AU:REG
Regis Healthcare Ltd.
 Sep 15, 2026 HOLD Hold
+6.7% avg upside
6 analysts
$5.00
12.02% Upside
 -3.2% ·
AU:SHL
Sonic Healthcare Limited
 Sep 15, 2026 HOLD Buy
+34.0% avg upside
12 analysts
$21.00
11.84% Upside
 -3.8% ·
AU:IDX
Integral Diagnostics Ltd.
 Sep 15, 2026 BUY Strong Buy
+40.2% avg upside
12 analysts
$3.20
44.75% Upside
 -5.6% ·
AU:ACL
Australian Clinical Labs Ltd
 Sep 15, 2026 HOLD Hold
-1.9% avg upside
6 analysts
$2.40
13.30% Downside
 -2.5% ·
RMD
Resmed
 Sep 15, 2026 BUY Buy
+4.1% avg upside
27 analysts
$262.00
17.96% Upside
 -3.2% ·
AU:ANN
Ansell
 Sep 15, 2026 HOLD Hold
-20.3% avg upside
9 analysts
$38.00
13.96% Downside
 +6.2% ·
AU:COH
Cochlear
Sep 15, 2026 HOLD Buy
+32.0% avg upside
15 analysts
$117.00
17.72% Downside
 +4.7% ·
TPR
Tapestry
 Jul 16, 2026 HOLD Strong Buy
+30.4% avg upside
28 analysts
$82.28
27.69% Downside
 -22.0% ·
AU:MVF
Monash IVF Group Ltd
 Jun 11, 2026 HOLD Buy
+31.6% avg upside
7 analysts
$0.72
2.79% Downside
 +9.9% ·
AU:ALC
Alcidion Group Limited
 May 18, 2026 HOLD Buy
+33.3% avg upside
2 analysts
$0.13
23.74% Upside
 -10.9% ·
AU:SEK
Seek Limited
 Oct 06, 2020 BUY Strong Buy
+106.6% avg upside
6 analysts
$31.60
185.42% Upside
 +39.8% ·
AU:CAR
CAR Group
 Oct 06, 2020 SELL Strong Buy
+57.7% avg upside
7 analysts
$16.04
25.97% Downside
 -17.1% ·
AU:ALQ
ALS
 May 22, 2019 SELL Strong Buy
+3.9% avg upside
4 analysts
$6.57
68.18% Downside
 +1.8% ·
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Craig Wong-Pan — Frequently Asked Questions
How accurate are Craig Wong-Pan's stock ratings?
Based on the calls 13Foresight could measure, about 59% of Craig's ratings were profitable over a one-year hold, with an average return of +2.9% per rating, or +15.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Craig ranked on 13Foresight?
Craig Wong-Pan is currently ranked #1885 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Craig cover?
Craig most recently has ratings on AU:HLS, AU:TLX, AU:CSL, AU:NAN, AU:RHC, AU:REG, AU:SHL, AU:IDX, AU:ACL, RMD, AU:ANN, AU:COH and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.